190 related articles for article (PubMed ID: 35303940)
1. BRD4 inhibitor GNE987 exerts anti-cancer effects by targeting super-enhancers in neuroblastoma.
Chen YL; Li XL; Li G; Tao YF; Zhuo R; Cao HB; Jiao WY; Li ZH; Zhu ZH; Fang F; Xie Y; Liao XM; Wu D; Wang HR; Yu JJ; Jia SQ; Yang Y; Feng CX; Yang PC; Fei XD; Wang JW; Xu YY; Qian GH; Zhang ZM; Pan J
Cell Biosci; 2022 Mar; 12(1):33. PubMed ID: 35303940
[TBL] [Abstract][Full Text] [Related]
2. An inhibitor of BRD4, GNE987, inhibits the growth of glioblastoma cells by targeting C-Myc and S100A16.
Ma L; Li G; Yang T; Zhang L; Wang X; Xu X; Ni H
Cancer Chemother Pharmacol; 2022 Dec; 90(6):431-444. PubMed ID: 36224471
[TBL] [Abstract][Full Text] [Related]
3. MZ1, a BRD4 inhibitor, exerted its anti-cancer effects by suppressing SDC1 in glioblastoma.
Li G; Ma L; Feng C; Yin H; Bao J; Wu D; Zhang Z; Li X; Li Z; Yang C; Wang H; Fang F; Hu X; Li M; Xu L; Xu Y; Liang H; Yang T; Wang J; Pan J
BMC Cancer; 2024 Feb; 24(1):220. PubMed ID: 38365636
[TBL] [Abstract][Full Text] [Related]
4. miR-766-5p Targets Super-Enhancers by Downregulating CBP and BRD4.
Gen Y; Muramatsu T; Inoue J; Inazawa J
Cancer Res; 2021 Oct; 81(20):5190-5201. PubMed ID: 34353856
[TBL] [Abstract][Full Text] [Related]
5. The BRD4 Inhibitor dBET57 Exerts Anticancer Effects by Targeting Superenhancer-Related Genes in Neuroblastoma.
Jia SQ; Zhuo R; Zhang ZM; Yang Y; Tao YF; Wang JW; Li XL; Xie Y; Li G; Wu D; Chen YL; Yu JJ; Feng CX; Li ZH; Zhou RF; Yang RD; Yang PC; Zhou B; Wan XM; Wu YM; Jiao WY; Zhou NN; Fang F; Pan J
J Immunol Res; 2022; 2022():7945884. PubMed ID: 36438198
[TBL] [Abstract][Full Text] [Related]
6. Super-enhancers and the super-enhancer reader BRD4: tumorigenic factors and therapeutic targets.
Qian H; Zhu M; Tan X; Zhang Y; Liu X; Yang L
Cell Death Discov; 2023 Dec; 9(1):470. PubMed ID: 38135679
[TBL] [Abstract][Full Text] [Related]
7. Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma.
Sengupta D; Kannan A; Kern M; Moreno MA; Vural E; Stack B; Suen JY; Tackett AJ; Gao L
Epigenetics; 2015; 10(6):460-6. PubMed ID: 25941994
[TBL] [Abstract][Full Text] [Related]
8. Concurrent targeting of MAP3K3 and BRD4 by
Liu C; Gen Y; Tanimoto K; Muramatsu T; Inoue J; Inazawa J
Mol Ther Nucleic Acids; 2021 Sep; 25():83-92. PubMed ID: 34258104
[TBL] [Abstract][Full Text] [Related]
9. PROTAC Bromodomain Inhibitor ARV-825 Displays Anti-Tumor Activity in Neuroblastoma by Repressing Expression of
Li Z; Lim SL; Tao Y; Li X; Xie Y; Yang C; Zhang Z; Jiang Y; Zhang X; Cao X; Wang H; Qian G; Wu Y; Li M; Fang F; Liu Y; Fu M; Ding X; Zhu Z; Lv H; Lu J; Xiao S; Hu S; Pan J
Front Oncol; 2020; 10():574525. PubMed ID: 33324552
[TBL] [Abstract][Full Text] [Related]
10. TAF Family Proteins and MEF2C Are Essential for Epstein-Barr Virus Super-Enhancer Activity.
Wang C; Jiang S; Zhang L; Li D; Liang J; Narita Y; Hou I; Zhong Q; Gewurz BE; Teng M; Zhao B
J Virol; 2019 Aug; 93(16):. PubMed ID: 31167905
[TBL] [Abstract][Full Text] [Related]
11. BRD4 PROTAC degrader ARV-825 inhibits T-cell acute lymphoblastic leukemia by targeting 'Undruggable' Myc-pathway genes.
Wu S; Jiang Y; Hong Y; Chu X; Zhang Z; Tao Y; Fan Z; Bai Z; Li X; Chen Y; Li Z; Ding X; Lv H; Du X; Lim SL; Zhang Y; Huang S; Lu J; Pan J; Hu S
Cancer Cell Int; 2021 Apr; 21(1):230. PubMed ID: 33888130
[TBL] [Abstract][Full Text] [Related]
12. Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition.
Henssen A; Althoff K; Odersky A; Beckers A; Koche R; Speleman F; Schäfers S; Bell E; Nortmeyer M; Westermann F; De Preter K; Florin A; Heukamp L; Spruessel A; Astrahanseff K; Lindner S; Sadowski N; Schramm A; Astorgues-Xerri L; Riveiro ME; Eggert A; Cvitkovic E; Schulte JH
Clin Cancer Res; 2016 May; 22(10):2470-81. PubMed ID: 26631615
[TBL] [Abstract][Full Text] [Related]
13. Disruption of super-enhancer-driven tumor suppressor gene RCAN1.4 expression promotes the malignancy of breast carcinoma.
Deng R; Huang JH; Wang Y; Zhou LH; Wang ZF; Hu BX; Chen YH; Yang D; Mai J; Li ZL; Zhang HL; Huang Y; Peng XD; Feng GK; Zhu XF; Tang J
Mol Cancer; 2020 Aug; 19(1):122. PubMed ID: 32771023
[TBL] [Abstract][Full Text] [Related]
14. Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma.
Kling MJ; Griggs CN; McIntyre EM; Alexander G; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
BMC Cancer; 2021 Sep; 21(1):1061. PubMed ID: 34565342
[TBL] [Abstract][Full Text] [Related]
15. p113 isoform encoded by CUX1 circular RNA drives tumor progression via facilitating ZRF1/BRD4 transactivation.
Yang F; Hu A; Guo Y; Wang J; Li D; Wang X; Jin S; Yuan B; Cai S; Zhou Y; Li Q; Chen G; Gao H; Zheng L; Tong Q
Mol Cancer; 2021 Sep; 20(1):123. PubMed ID: 34579723
[TBL] [Abstract][Full Text] [Related]
16. Super enhancers targeting ZBTB16 in osteogenesis protect against osteoporosis.
Yu W; Xie Z; Li J; Lin J; Su Z; Che Y; Ye F; Zhang Z; Xu P; Zeng Y; Xu X; Li Z; Feng P; Mi R; Wu Y; Shen H
Bone Res; 2023 Jun; 11(1):30. PubMed ID: 37280207
[TBL] [Abstract][Full Text] [Related]
17. BRD4 Connects Enhancer Remodeling to Senescence Immune Surveillance.
Tasdemir N; Banito A; Roe JS; Alonso-Curbelo D; Camiolo M; Tschaharganeh DF; Huang CH; Aksoy O; Bolden JE; Chen CC; Fennell M; Thapar V; Chicas A; Vakoc CR; Lowe SW
Cancer Discov; 2016 Jun; 6(6):612-29. PubMed ID: 27099234
[TBL] [Abstract][Full Text] [Related]
18. FUBP1 promotes neuroblastoma proliferation via enhancing glycolysis-a new possible marker of malignancy for neuroblastoma.
Jiang P; Huang M; Qi W; Wang F; Yang T; Gao T; Luo C; Deng J; Yang Z; Zhou T; Zou Y; Gao G; Yang X
J Exp Clin Cancer Res; 2019 Sep; 38(1):400. PubMed ID: 31511046
[TBL] [Abstract][Full Text] [Related]
19. AZD5153, a Bivalent BRD4 Inhibitor, Suppresses Hepatocarcinogenesis by Altering BRD4 Chromosomal Landscape and Modulating the Transcriptome of HCC Cells.
Lin CH; Kuo JC; Li D; Koenig AB; Pan A; Yan P; Bai XF; Lee RJ; Ghoshal K
Front Cell Dev Biol; 2022; 10():853652. PubMed ID: 35399501
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic Targeting of
Huang M; Zeki J; Sumarsono N; Coles GL; Taylor JS; Danzer E; Bruzoni M; Hazard FK; Lacayo NJ; Sakamoto KM; Dunn JCY; Spunt SL; Chiu B
Cancer Res; 2020 Mar; 80(5):1024-1035. PubMed ID: 31900258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]